Phase II study of gemcitabine in patients with advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34732138

about

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer Acute myocardial infarction following gemcitabine therapy--a case report Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments.A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Gemcitabine and platinum combinations in pancreatic cancer.Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer Gemcitabine-induced cardiomyopathy: a case report and review of the literature.Novel non-operative treatment and treatment strategies in pancreatic cancer.Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas Pancreatic cancer: the evolving role of systemic therapy.Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.Metastatic pancreatic cancer.Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.Systemic therapy for metastatic pancreatic adenocarcinoma.Developments in the systemic therapy of pancreatic cancer.Systemic therapy for advanced pancreatic cancer.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Long-time survival of a patient with metastatic pancreatic cancer: a case report Advanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Gemcitabine-induced severe pulmonary toxicity.A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer Adjuvant and neoadjuvant treatment in pancreatic cancer Gemcitabine therapy in patients with advanced pancreatic cancer Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

P2860

Q24657439-A6A4E359-655F-4D02-ACE8-1FE739E3269F Q28378024-0DD4BB60-56BB-4439-A5AD-33CEA95B1441 Q29937967-466C3C1D-F551-4E25-8EDC-A58694C73534 Q30438645-71A6CEE4-1038-48D3-B468-9302561C8619 Q30502529-793F561F-D58F-42BA-91D4-EE4D256E8923 Q31094242-6255F6AE-1ADA-4B51-85EC-AEB9F02F611F Q33282550-FB73952D-2050-4202-92B0-E9A6CD90B099 Q33327923-2764EF58-1374-4298-960C-925272A464DC Q33329493-B59AF426-449F-43F3-9AD2-D06068E4514B Q33344048-DAEE2920-4106-4C06-93A9-8E59ABF6D29F Q33347231-A364E612-1D9A-4384-BAD3-17C1FB7814B2 Q33363936-8B15942B-AF2E-4171-9BE7-133C16289F9B Q33370969-DCF214D4-07D5-4ECF-B1BF-0B4D50A1E395 Q33402374-00B4FD14-FDAA-43EB-A9E0-908F8C42C6D5 Q33409519-DA7E70C7-760B-443F-882B-BC7FF0D5C844 Q33428016-7942283D-C5D3-4BE0-A56C-6DA17C2C446C Q33863038-6DBE970C-63B6-4104-B898-CFD9BAC6B58C Q34074879-A9F70188-B351-4FBA-AD3C-7139C75137A7 Q34449812-18315BB1-B9CF-4E0A-A3EB-4AC3E02FBA70 Q34515547-58EFD5AE-5BA0-49BD-A26A-ABB19838EECF Q34605189-DF8F35DF-B3F1-4C5A-9595-41CC128308EC Q34632760-DC721702-8B31-41D6-B049-E0F6854AFDC2 Q34768090-407723BA-FAFB-4ACE-A65E-524F1C280271 Q34810745-FC3E3524-5561-4A78-89E2-7382EDDCAC7D Q34976873-9DCB551B-52F3-44C9-9CAC-0505238D4040 Q35038451-785590EA-6EB8-4785-A5E4-BD9FC79D22D2 Q35076238-507FA00C-9E05-4B6C-9240-869D1EC00F9E Q35087326-6AC0E284-2A5A-4D60-8CFE-A38E33AABA7C Q35089138-0E13DBF5-903F-4193-9C42-6D8E769048C2 Q35144004-4247BE90-69A7-436A-94BD-CABCF2D9458D Q35225648-CF7D2769-061B-48AD-B20B-6A79253C0422 Q35576200-9D491A44-CDF0-46BA-8BA8-DCE0D231D7E3 Q35599597-6F1BCA05-8E7B-4327-8D37-B63CAC6A58C6 Q35641366-54A6635D-F602-49F4-B1A4-DC27702BF2E2 Q35745690-B40D36EA-AD09-4F53-A2C6-35B979247C44 Q35886631-B6BDE718-D8AE-47A9-A97E-8DA431CA941D Q35937445-983B30A5-8F89-4601-84C7-A6EF264C3D30 Q36114508-C7121D60-57C1-4919-AA79-3C9C7C52280A Q36211616-D716585A-EA33-4EC5-872E-460BA43B5C2B Q36294910-7D6D5F06-31BC-4E1B-9642-5E4AF7D46919

P2860

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34732138

description

1996 nî lūn-bûn

@nan

1996 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@ast

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@en

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@nl

type

label

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@ast

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@en

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@nl

prefLabel

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@ast

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@en

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@nl

P1433

Q34732138-65E9A765-EED4-447D-9E58-163DE24DD542

P1476

Q34732138-32B1442D-AF35-4900-9097-54FE41360C84

P2093

Q34732138-529167E9-61C9-4612-9C5B-3D449C9B46F7

Q34732138-5B073F8E-F3C3-48AA-BE31-14B9D6E68DDD

Q34732138-9D540481-516F-4703-9FA0-F64D2CFFAB96

Q34732138-A3497582-8FDC-4AC3-9067-F4304A3DF18D

Q34732138-B4D75A11-2493-4419-AA0B-3CFF8A7FBD15

Q34732138-C91DB2B5-DB0E-408E-8402-59A56D1EB773

Q34732138-E0559748-A78E-4F04-8352-0A734D6305D3

P2860

Q34732138-04F90A1C-D72E-4EF0-9C32-9D602F4479ED

Q34732138-336691E2-3677-45B1-89D4-9A83BD6E7E30

Q34732138-417E82F8-A9C6-43F2-85C3-A08EB8631B0B

Q34732138-72FF2BCC-C591-419B-B54F-3555178D9F17

Q34732138-BB4018F8-B730-4049-A060-5911E69223C4

Q34732138-E4347DCE-D483-430A-B7EE-B3B7A24D6AE0

Q34732138-FE5F1C24-357C-4473-B70C-2E6D0A00D49B

P2888

Q34732138-6256E6B5-ABEF-4978-BC0D-CD28887020AE

P304

Q34732138-C936437A-A098-4119-8AC1-77D446F7668B

P31

Q34732138-E62AEF23-4F0F-4FBD-9816-8D425EFBEC54

P356

Q34732138-A55FF5E6-3E16-41F4-B91A-7EA0F8E0C80C

P407

Q34732138-0788D8F0-FDA9-4C89-8D31-B388FDFE8A52

P433

Q34732138-EB5916C6-9EF0-4391-996D-C788F19BF219

P478

Q34732138-E9089C94-45F6-41E0-B9A7-5F395C53DC97

P577

Q34732138-EB122A51-B510-4852-8AF7-2BFC6562ADB8

P5875

Q34732138-C5592C32-0B84-4DD6-9BBF-983B8EBA18AD

P6179

Q34732138-4088D298-9B83-47EB-8B62-E3CCF60C4CFA

P698

Q34732138-5A6BB836-2AB3-4A2A-A31C-08F6B2646EC6

P921

Q34732138-642902F6-7A38-4527-A7CC-795AEDB4B8C9

P932

Q34732138-7A33F61D-5A7B-485A-ACF0-01C4239CA971

P356

P1433

British Journal of Cancer

P1476

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

@en

P2093

A L Harris

http://www.w3.org/2001/XMLSchema#string

G Spiessi

http://www.w3.org/2001/XMLSchema#string

J Blatter

http://www.w3.org/2001/XMLSchema#string

J Carmichael

http://www.w3.org/2001/XMLSchema#string

M F Spittle

http://www.w3.org/2001/XMLSchema#string

R C Russell

http://www.w3.org/2001/XMLSchema#string

U Fink

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

P2888

P304

101-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1996.18

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

1996-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14645495

http://www.w3.org/2001/XMLSchema#string

P6179

1011815301

http://www.w3.org/2001/XMLSchema#string

P698

8554969

http://www.w3.org/2001/XMLSchema#string

P921

P932

2074288

http://www.w3.org/2001/XMLSchema#string